Who is Entasis Therapeutics?

Entasis Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens.

How much does ettx's acquisition cost entasis?

The acquisition price of $2.20 per share represents a premium of 22.2% to ETTX’s closing price on May 23. Shares of Entasis rose 21.1% on May 23, following the deal announcement. The stock has dipped 0.5% in the year so far compared with the industry’s 24.9% decline.

Will Innoviva buy entasis (ettx)?

Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022. Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Entasis Therapeutics Holdings Inc. (NasdaqGM:...